Biotech Values

[rfj1862]

Then how did PFE’s Pavlovid manage to do $22B in 2022 sales??

Because it was really the only decent antiviral option in 2022 (setting aside remdesivir and the Ridgeback Bio drug) and I believe it was not being used appropriately in that most doctors were likely prescribing it well outside the window of efficacy. Further, insurance companies were likely not exerting much control on prescriptions in 2022.

I suspect you will say a massive dropoff in sales in 2023, both as COVID rates decline and as insurance companies become much more stringent about when it can be prescribed.